Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
16,121 stopped studies · 89% state a reason
Over the 16,121 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03362606 | Engineered Immune Effectors Against Ovarian Cancer | Phase 1 / Phase 2 | terminated | Dec 5, 2017 | Shenzhen Geno-Immune Medical Institute | not stated | Not stated |
| NCT03362619 | Engineered Immune Effectors Against Cervical Cancer | Phase 1 / Phase 2 | terminated | Dec 5, 2017 | Shenzhen Geno-Immune Medical Institute | not stated | Not stated |
| NCT03535246 | Immunotherapy Based on Tumor Associated Antigen-specific Immune Effector Cells | Phase 1 / Phase 2 | terminated | May 24, 2018 | Shenzhen Geno-Immune Medical Institute | not stated | Not stated |
| NCT04010877 | Multiple CAR-T Cell Therapy Targeting AML | Phase 1 / Phase 2 | terminated | Jul 8, 2019 | Shenzhen Geno-Immune Medical Institute | not stated | Not stated |
| NCT04019327 | A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer | Phase 1 / Phase 2 | terminated | Jul 15, 2019 | Memorial Sloan Kettering Cancer Center | Study terminated by sponsor | Other (stated, no rule matched) |
| NCT04085159 | Immunotherapy Based on Antigen-specific Immune Effector Cells Targeting Neurofibromatosis… | Phase 1 / Phase 2 | terminated | Sep 11, 2019 | Shenzhen Geno-Immune Medical Institute | not stated | Not stated |
| NCT04427449 | 4SCAR-CD44v6 T Cell Therapy Targeting Cancer | Phase 1 / Phase 2 | terminated | Jun 11, 2020 | Shenzhen Geno-Immune Medical Institute | not stated | Not stated |
| NCT04430530 | 4SCAR-T Therapy Post CD19-targeted Immunotherapy | Phase 1 / Phase 2 | terminated | Jun 12, 2020 | Shenzhen Geno-Immune Medical Institute | not stated | Not stated |
| NCT05262673 | NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL | Phase 1 | terminated | Mar 2, 2022 | Shenzhen Geno-Immune Medical Institute | not stated | Not stated |
| NCT05277753 | NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL | Phase 1 | terminated | Mar 14, 2022 | Shenzhen Geno-Immune Medical Institute | not stated | Not stated |
| NCT05436509 | CD19/79b Bi-specific CAR-T Cell Therapy | Phase 1 / Phase 2 | terminated | Jun 29, 2022 | Shenzhen Geno-Immune Medical Institute | not stated | Not stated |
| NCT05437328 | GD2/CD56 Bi-specific CAR-T Cell Therapy | Phase 1 / Phase 2 | terminated | Jun 29, 2022 | Shenzhen Geno-Immune Medical Institute | not stated | Not stated |
| NCT05437341 | PSMA/CD70 Bi-specific CAR-T Cell Therapy | Phase 1 / Phase 2 | terminated | Jun 29, 2022 | Shenzhen Geno-Immune Medical Institute | not stated | Not stated |
| NCT05780879 | A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission… | Phase 2 | terminated | Mar 23, 2023 | University of Michigan Rogel Cancer Center | Interim Analysis per Protocol | Efficacy / futility |
| NCT06385262 | TOP 2301: Neoadjuvant Chemo for NSCLC | Phase 2 | suspended | Apr 26, 2024 | Duke University | Protocol is currently undergoing study design revisions and will re-open after amendment is IRB… | Other (stated, no rule matched) |
| NCT06620302 | Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment… | Phase 1 / Phase 2 | suspended | Oct 1, 2024 | Children's Oncology Group | Unacceptable Toxicity | Safety / toxicity |
| NCT06802523 | Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and… | Phase 1 | suspended | Jan 31, 2025 | National Cancer Institute (NCI) | Drug Supply Issues | Drug supply |
| NCT07068555 | Prostate Cancer Vaccines | Phase 1 / Phase 2 | terminated | Jul 16, 2025 | Shenzhen Geno-Immune Medical Institute | not stated | Not stated |
| NCT07193966 | NG2 and DLL3 CAR-T Cells Targeting Melanoma | Phase 1 / Phase 2 | terminated | Sep 26, 2025 | Shenzhen Geno-Immune Medical Institute | not stated | Not stated |
| NCT03728335 | Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation | Phase 2 | suspended | Nov 2, 2018 | City of Hope Medical Center | Accrual goal met | Enrollment / accrual |
| NCT04949256 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus… | Phase 3 | terminated | Jul 2, 2021 | Merck Sharp & Dohme LLC | Trial was rendered as cancelled work ongoing in the book of business. | Sponsor / business decision |
| NCT06250036 | Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer(ZODIAC) | Phase 2 | suspended | Feb 8, 2024 | Royal Marsden NHS Foundation Trust | Gilead's ongoing evaluation of the wider Zimberelimab and Domvanalimab programme, following the… | Safety / toxicity |
| NCT06364748 | Expanding Access to Care Through Telemedical Support for Vital Sign Monitoring in… | N/A | terminated | Apr 15, 2024 | West Michigan Cancer Center | Dr. Shalowitz resigned from the West Michigan Cancer Center. Target enrollment was 60 and only 18… | Efficacy / futility |
| NCT07214662 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a… | Phase 1 | terminated | Oct 9, 2025 | Genentech, Inc. | The trial was terminated due to sponsor decision. | Sponsor / business decision |
| NCT02392572 | ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk… | Phase 1 / Phase 2 | terminated | Mar 19, 2015 | M.D. Anderson Cancer Center | \<75% participants | Other (stated, no rule matched) |
| NCT03274258 | Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma | Phase 2 | terminated | Sep 6, 2017 | M.D. Anderson Cancer Center | The study met its prespecified futility criteria during the prespecified interim futility analysis… | Efficacy / futility |
| NCT04473781 | Interstitial Brachytherapy for the Treatment of Unresectable/Unablatable Kidney Cancer | Phase 1 | terminated | Jul 16, 2020 | Jonsson Comprehensive Cancer Center | slow Accrual | Enrollment / accrual |
| NCT05580770 | Mirdametinib + BGB-3245 in Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Oct 14, 2022 | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | Lack of tolerability of BGB-3245 (Brimarafenib) when given in combination with Mirdametinib | Other (stated, no rule matched) |
| NCT05724602 | Radiotherapy Plus Xevinapant in Older Patients With Locally Advanced Head and Neck…(RAVINA) | Phase 2 | terminated | Feb 13, 2023 | European Organisation for Research and Treatment of Cancer - EORTC | discontinuation of all ongoing studies involving xevinapant | Other (stated, no rule matched) |
| NCT06133790 | Profiles of Expression in HPV+ Versus HPV Head and Neck Cancers(HPVNGS) | — | withdrawn | Nov 15, 2023 | GCS Ramsay Santé pour l'Enseignement et la Recherche | Feasibility issue | Other (stated, no rule matched) |
| NCT06200103 | Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate… | Phase 2 | suspended | Jan 10, 2024 | Mayo Clinic | Pending additional funding. | Funding |
| NCT06202066 | Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients… | Phase 2 | suspended | Jan 11, 2024 | Roswell Park Cancer Institute | pending protocol changes | Other (stated, no rule matched) |
| NCT06315491 | A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer | Phase 2 | terminated | Mar 18, 2024 | Cybrexa Therapeutics | Limited clinical activity | Other (stated, no rule matched) |
| NCT06595563 | HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for…(ZEPHIR-02) | Phase 2 | terminated | Sep 19, 2024 | Jules Bordet Institute | Study logistics or limited study population, as defined by the iclusion/exclusion criteria, leading… | Enrollment / accrual |
| NCT06643455 | Mindfulness Intervention for Improving Nutrition in the Digital Kitchen Among Stage I-III… | N/A | terminated | Oct 16, 2024 | Fred Hutchinson Cancer Center | Difficulties in recruitment | Enrollment / accrual |
| NCT06754215 | Smoking Cessation Intervention Development for Homeless Youth | N/A | terminated | Dec 31, 2024 | Ohio State University Comprehensive Cancer Center | The study did not progress to full completion due to an unanticipated prolonged medical leave of… | Investigator |
| NCT00126230 | Trial of Docetaxel-samarium in Patients With Hormone-refractory Advanced Prostate Cancer | Phase 2 | terminated | Aug 3, 2005 | Gustave Roussy, Cancer Campus, Grand Paris | not stated | Not stated |
| NCT00346645 | A Phase II Study of Velcade® in Patients Stage IIIB OR IV Non-Small Cell Lung Cancer | Phase 2 | terminated | Jun 30, 2006 | Gustave Roussy, Cancer Campus, Grand Paris | stopped after planned interim analysis for lack of efficacy | Efficacy / futility |
| NCT02417168 | Procalcitonin Levels as a Predictor of Bacteremia in Febrile Pediatric Oncology… | — | terminated | Apr 15, 2015 | CAMC Health System | PI left study site | Investigator |
| NCT02702310 | Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed… | — | suspended | Mar 8, 2016 | Vanderbilt-Ingram Cancer Center | Treatment unavailable at facility | Other (stated, no rule matched) |
| NCT03606070 | Multiparametric PET-MRI Integration for a New Approach to Tumor Heterogeneity in…(IMAHTEP) | N/A | terminated | Jul 30, 2018 | Gustave Roussy, Cancer Campus, Grand Paris | Lack of inclusion | Other (stated, no rule matched) |
| NCT04803084 | Multiparametric MRI as a Non-Invasive Biomarker of the Tumor Microenviroment | — | suspended | Mar 17, 2021 | Laura Kennedy | MRI upgrade | Other (stated, no rule matched) |
| NCT05494697 | Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With… | Phase 2 | suspended | Aug 10, 2022 | AIM ImmunoTech Inc. | A business decision to place screening/enrollment on hold. Study redesign/amendment pending… | Enrollment / accrual |
| NCT05497336 | A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated… | Phase 1 | terminated | Aug 11, 2022 | Innovent Biologics (Suzhou) Co. Ltd. | company development strategy adjustment | Sponsor / business decision |
| NCT05827614 | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR…(POTENTIATE) | Phase 1 | terminated | Apr 25, 2023 | Boundless Bio, Inc. | Decision was made to halt the study based on overall clinical experience and market considerations.… | Safety / toxicity |
| NCT07090174 | CASCADE: Testing for Safety and Immune Effects of PDS0101, an Anti-HPV Therapy, Among… | Phase 2 | withdrawn | Jul 29, 2025 | University of California, San Diego | Study withdrawn prior to participant enrollment due to lack of study product. | Enrollment / accrual |
| NCT07408089 | Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or…(KOMODO-1) | Phase 1 | terminated | Feb 12, 2026 | Boundless Bio, Inc. | The study was terminated primarily due to a business decision related to a corporate transaction… | Safety / toxicity |
| NCT07556757 | A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic… | Phase 1 | terminated | Apr 29, 2026 | ImmunityBio, Inc. | Study was terminated prematurely by the Sponsor for reasons not related to the safety of study drug | Safety / toxicity |
| NCT07660458 | Parental Distress and Treatment Adherence in Pediatric Recurrent Medulloblastoma | — | withdrawn | Jun 22, 2026 | West China Hospital | Study withdrawn prior to enrollment due to administrative review | Enrollment / accrual |
| NCT03173950 | Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers | Phase 2 | terminated | Jun 2, 2017 | National Cancer Institute (NCI) | Support was withdrawn from study resulting in early termination of study. Investigator had to close… | Drug supply |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 24, 2026source: clinicaltrials